| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.068 | 0.2 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.2 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |